CollPlant Biotechnologies Ltd. (CLGN) - Debt to Equity

This chart illustrates the market value of CollPlant Biotechnologies (CLGN) with the 0.95 metric, accompanying a company that develops innovative solutions for tissue regeneration and aesthetics. CollPlant Biotechnologies (CLGN) utilizes a unique tobacco-derived protein that is identical to human collagen, eliminating the risk of allergic reactions. The business model relies on licensing hydrogels to medical behemoths, ensuring high profitability without the capital expenditures associated with plant construction.

This indicator measures the total debt load relative to equity, allowing investors to determine the balance between borrowed financing and the company's internal resources. By analyzing the degree of equity leverage on GURU.Markets, the market assesses the financial stability of CollPlant Biotechnologies (CLGN), which is supported by a stable core of leading bioengineers, thereby minimizing operational risks when scaling R&D projects.